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Abstract 
 8-Hydroxyquinoline derivatives are metal-binding compounds that have recently awakened  
interest as therapeutic agents for cancer therapy. In this scenario, we designed and synthesized three 
new glucoconjugates, 5,7-dichloro-8-quinolinyl-β-D-glucopyranoside, 5-chloro-8-quinolinyl-β-D-
glucopyranoside and 2-methyl-8-quinolinyl-β-D-glucopyranoside and investigated their biological 
properties in comparison to the parent 8-hydroxyquinoline derivatives.  Our in vitro data show 
that 2 out of 3 glycosilated compounds possess a pharmacologically-relevant antiproliferative 
activity against tumor cells, similar to that of their parent compounds; this activity is associated with 
a relevant triggering of apoptosis. The pharmacological profile of the investigated compounds 
depends on the cellular enzymatic -glucosidase activity, as demonstrated by the inhibition of  
antiproliferative activity in the presence of the 2,5-dideoxy-2,5-imino-D-mannitol.  
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Introduction 
 Cancer, the uncontrolled and pathological proliferation of abnormal cells, is the second 
leading cause of human death after cardiovascular diseases in developing, as well as advanced, 
countries.
1,2 
Although there are many therapeutic strategies, including chemotherapy and 
radiotherapy, high systemic toxicity and drug resistance limit the successful outcomes in most 
cases. Therefore, novel treatments are urgently needed for cancer therapy. 
 8-Hydroxyquinoline derivatives (OHQs) are metal-binding compounds that have recently 
been viewed with interest as therapeutic agents for cancer and Alzheimer disease (AD)
 3
. Clioquinol 
(5-chloro-7-iodo-8-hydroxyquinoline, CQ) is the most known member of this family. In the 1950s, 
it was widely used as an amebicide for the treatment of diarrhea
4
. CQ has widely been investigated 
as a metal-protein-attenuating compound. It also reached clinical trials for the treatment of AD 
disease, but clinical studies have been interrupted due to issues with the purity of large-scale CQ 
production: small amount of di-iodo-8-hydroxyquinoline, known carcinogen, contaminated CQ 
production. Currently, CQ is in phase I clinical trial in patients with hematologic malignancy, such 
as leukemia, myelodysplasia, non-Hodgkin’s and Hodgkin’s lymphomas, and multiple myeloma.5 
 The anticancer mechanism of OHQs is related to the complexation of copper ions
6
. This 
transition metal ion is involved in many different cellular mechanisms: as cofactor for different Cu-
dependent oxidases in respiration processes and in other proteins.
7
 Even if copper homeostasis is 
tightly regulated, elevated copper level have been found in many types of cancer. Although its 
accumulation in cancer cells has not yet been fully explained, it is conceivable that Cu
2+
 may help 
the tumor in its growth and release of metastatic cells. In particular, Cu
2+
 is necessary for 
angiogenesis,
8,9
 that is the mechanism by which the tumor may survive and grow beyond one or two 
millimeters of diameter. The need for Cu
2+
 ions by tumor cells justified the clinical use of specific 
Cu
2+ 
chelators as anticancer agents 
10,11,12
. It is important to note that the use of Cu complexes as 
cancer therapeutics is likely dependent more on their cytotoxic action, rather than modulation of Cu 
homeostasis.
13 Although the mechanism of action is not completely understood, experimental 
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evidence suggests that OHQs and CQ act as anticancer agents as 20S proteasome inhibitors in the 
presence of copper(II).
14,15
 Other mechanisms have been reported to explain the cytotoxicity of CQ, 
such as induction of the cytoplasmatic clearance of X-linked inhibition of apoptosis protein
16
 and  
induction of DNA double strand-breaks.
17
 
The crucial role played by Cu
2+
 ions in many cellular mechanisms also explains how an 
uncontrolled depletion of Cu
2+
 could be the cause of toxic events. For this reason, unselective 
chelation of essential metal ions due to an anticancer treatment could have severe side effect and 
should therefore be avoided. A well-accepted strategy to prevent these side effects from occurring 
consists in using prodrugs. 
 In very general terms, prodrug design aims to overcome a number of limitations of drug 
candidates:
18
 a) pharmaceutical problems, such as poor solubility, insufficient chemical stability, 
unacceptable taste or odor, and irritation or pain; b) pharmacokinetic problems, such as insufficient 
oral absorption, inadequate blood-brain barrier permeability, marked pre-systemic metabolism, and 
toxicity; and c) pharmacodynamic problems, such as low therapeutic index and lack of selectivity at 
the site of action.  
 For cancer therapy, glucose-conjugated prodrugs are of great interest since they can enhance 
uptake of a drug in cancer cells, as tumor cells require a significant amount of glucose. In fact the 
efficiency of ATP production in normal cells does not satisfy the high energy requirements of 
cancer cells and thus glucose transporters (GLUTs) are overexpressed in cancer cells to improve 
glucose uptake.
19
 The ratio of GLUTs expression in malignant versus normal cells is about 100-
300.
20
  
 Once delivered to the target tissue, non-cytotoxic prodrugs require tumor-specific activation. 
This may occur by the hypoxic environment of solid tumors, by the tumor-associated proteases or 
by the enzymes selectively present in the tumor. Prodrug monotherapy is a convenient strategy to 
activate prodrugs using an enzyme already present in the tumor. In particular, appropriate 
glycosylated prodrugs are activated by -glucosidase overexpressed in tumor cells.21 
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 Summing-up, glycosylated prodrugs of copper-binding compounds such as OHQs could 
combine a selective delivery to tumor tissues with a tumor specific mechanism of activation and 
specific antitumor activity and therefore could represent a new strategy for the research of 
anticancer agents. In addition the presence of the sugar unit prevents copper(II) binding and could 
prevent the systemic undesired complexation. Moreover, glycosylated prodrugs of OHQs are 
expected to be more soluble than corresponding parent compounds and therefore more in line with 
drug-likeness criteria. 
 In a previous explorative study we showed for the first time the antiproliferative activity of 
5-chloro-7-iodo-8-quinolinyl-β-D-glucopyranoside (GluCQ) and for comparison of 8-
hydroxyquinoline glucoconjugate (GluOHQ) as new prodrugs
22
. In particular, we observed that 
these compounds show significant antiproliferative activities against different cancer cell lines in 
the presence of copper(II). We also hypothesized that the glucose moiety had to be cleaved in cells 
by the β-glucosidase and then the aglycone was able to complex copper(II) ions. In this paper we 
describe the synthesis of three new glyconjugates of OHQs (Figure 1) with good physicochemical 
and ADME profile, the characterization and stability, the chelating properties of copper ions, the in 
vitro anticancer biological profile and, finally, some docking experiments to shed light on 
experimental results. We clarify some aspects of the action mechanism of the glycosylated 
derivatives by demonstrating the role of the β-glucosidase enzyme. For comparative purposes, the 
data for the corresponding 8-hydroxyquinolines were also collected (Figure 1).  
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Figure 1.  Chemical structures of investigated compounds 
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Results  
In silico physicochemical and ADME profile. Lipinski's Rule of Five (Ro5) is a widely accepted 
rule of thumb to determine if a chemical compound with a certain pharmacological or biological 
activity has molecular properties (i.e. the molecular weight is over 500 Da, the calculated log P is 
over 5, the structure includes more than 5 hydrogen-bond donors and more than 10 hydrogen-bond 
acceptors) that could be associated with poor absorption and distribution properties. Designed 
compounds (Figure 1) were tested by Ro5. The results revealed that all compounds are within the 
range set by Ro5 as per Table 1.  
 Properties included in the Ro5 may vary with molecular flexibility. To check the extent of 
the influence of flexibility on the 3D structure of the glycosylated prodrugs we monitored 
lipophilicity, which is widely accepted as the most relevant molecular property associated to 
biodistribution.
23
 In practice, we firstly submitted all prodrugs to a conformational analysis. Then 
we calculated the log P of any resulting conformer (called virtual log P
24
), the average log P value, 
and the lipophilicity range (i.e. the difference between the highest and the lowest virtual log Ps). 
Data in Table 1 show that the influence of molecular flexibility is modest (lipophilicity range lower 
than 0.5). 
 Solubility is a key property in drug discovery. In this study, solubility data of investigated 
compounds are of computational nature and expressed as ALOGpS (the higher, the more soluble 
the compound, see Experimental Part for more details) and reported in Table 1. They point out that 
prodrugs are expected to be more soluble than corresponding drugs.  
 Finally, to predict the ADME behaviour, the compounds under study were projected on the 
following pre-calculated models implemented in the VolSurf+ software (see Experimental Part for 
more details): plasma protein affinity (PB), distribution volume (VD), Caco-2 cell permeability 
(CACO2), blood–brain barrier permeation (lgBB) and metabolic stability (MetStab). The ADME 
profiles of compounds  (Table 1) were evaluated according to the rules proposed by Carosati et al.
25
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Most values are in line with the alert threshold values of drug-likeness. The low absorption 
predicted by the CACO2 descriptor (0.2 the lowest acceptable threshold) has limited relevance here 
since absorption is expected to be related to active transport mechanisms. 
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Table 1. Lipinski’s Ro5, lipophilicity, solubility and ADME descriptors of investigated compounds. 
 Ro5 descriptors Lipophilicity Solubility ADME descriptors 
Compounds MW 
a)
 HBD 
a)
 
HBA 
a)
 
LOGP 
a)
 
Ro5 violation 
a)
 
averaged log P 
b)
 
range
 
b)
 
LOGpS 
c)
 PB 
d)
 
VD 
d)
 
CACO2 
d)
 
LgBB 
d)
 
MetStab 
d)
 
Cl2HQ 214.05 1 2 3.15 0 Nc 
e)
 Nc 
e)
 -3.19 88 0.09 1.12 0.42 90 
ClHQ 179.60 1 2 2.47 0 Nc 
e)
 Nc 
e)
 -2.33 78 0.17 1.19 0.37 98 
MeHQ 159.18 1 2 2.23 0 Nc 
e)
 Nc 
e)
 -1.95 70 0.28 1.29 0.33 94 
GluCl2HQ 376.19 4 7 0.56 0 1.09 0.11 -2.3 29 0.12 -0.47 -1.12 100 
GluClHQ 341.74 4 7 -0.05 0 0.54 0.09 -1.87 32 0.14 -0.48 -1.22 100 
GluMeHQ 321.33 4 7 -0.29 0 0.76 0.09 -1.69 24 0.21 -0.42 -1.29 100 
OHQ 145.16 1 2 1.83 0 Nc 
e)
 Nc 
e)
 -1.54 66 0.17 1.17 0.29 100 
CQ 289.50 0 1 4.08 0 Nc 
e)
 Nc 
e)
 -4.09 93 0.30 1.62 0.65 68 
GluOHQ 307.30 4 7 -0.69 0 -0.04 0.09 Nd 
f)
 18 0.17 -0.53 -1.31 100 
GluCQ 467.64 4 7 0.88 0 1.56 0.11 -2.83 35 0.12 -0.43 -1.13 100 
 
a) Calculated by VolSurf+; definitions: MW= Molecular Weight, HBD = number of hydrogen bond donor groups, HBA = number of hydrogen 
bond acceptor groups, LOGP = logarithm of the partition coefficient, Ro5 violations = number of violations to the Ro5. 
b) Calculated with VEGA ZZ 3.0.0; definitions: averaged log P = averaged log P value calculated using log Ps calculated on the series of 
conformers (virtual log Ps), range = difference between the largest and the lowest virtual log P values. 
c) Calculated by VCCLAB; definition: LOGpS = minus logarithm of the solubility values calculated by the software. A solubility larger than -4 is 
considered with drug likeness criteria. 
d) Calculated by VolSurf+; definitions: PB = percentage of protein binding, VD = distribution volume [l/kg], CACO2 = qualitative value of cells 
permeability, lgBB = logarithm of the Blood-Brain Barrier distribution, MetStab = percentage of the remaining compound after incubation with 
human CYP3A4 enzyme. The following drug likeness criteria were used to evaluate data: PB lower than 90%, CACO2 lowest threshold value 0.2; 
lgBB lower than -0.5 indicate very poor brain penetration, values greater than 0.5 indicate high brain penetration; MetStab greater than 50 indicate 
stable behaviour. 
e) Not calculated. f) Not determined. 
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Chemistry 
Synthetic aspect. The new compounds GluCl2HQ, GluClHQ and GluMeHQ were synthesized by a 
modified Michael procedure as reported by us
222
 for similar compounds (scheme 1). The desired 
compounds were achieved through a one-pot reaction. Briefly, the quinoline compounds were 
dissolved in a water/methanol solution of the base K2CO3 and then a solution of glycosyl bromide 
in dichloromethane was added together with a phase transfer catalyst, such as tetrabutylammonium 
salts. This reaction produced the β-anomer of the glycosides. The pure products were isolated by 
precipitation. All novel compounds were characterized by 
1
H NMR and 
13
C NMR spectroscopy as 
well as ESI-MS. NMR spectra confirm the identity of the products.  
 
 
Scheme 1. Reagents and conditions: (a) K2CO3(aq), Bu4NBr,CH2Cl2, 68h, r.t. 
 
The ESI spectra of glucoconjugates show at least three peaks due to proton and sodium adduct ion 
and the dimeric sodium adduct ion. Furthermore, the zoom scan spectra of the halogenated 
compounds show typical isotopic patterns due to the presence of the halogen atoms. 
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Figure 2. NMR spectra of  the glucoconjugates at 500 MHz in MeOD. GluCl2HQ (up), GluClHQ 
(middle), MeHQ (down).  
 The 
1
H NMR spectra of glucoconjugates are reported in Figure 2. In all the spectra the 
signals due to the quinoline moiety and the signals due to the sugar moiety can be seen. The J1,2 
values of the glucose ring (about 7.8 Hz) confirm the β configuration for all derivatives. The H-1 of 
the glucose moiety is downfield shifted because of the deshielding effect of the aromatic ring as 
reported for similar compounds and resonates at about 5.1 ppm.
26
 The presence of chlorine at C-7 
position in GluCl2HQ further shifts the H-1 downfield at about 5.4 ppm. The glucose protons of 
GluCl2HQ are more shifted upfield in comparison to other two glycoconjugates as reported 
elsewhere for CQ glyconjugates. The disposition of the aromatic ring compared to the sugar unit 
affects the chemical shifts especially of glucose H-5 and H-6.   
 CD spectra of the three new compounds (Figure 3) were also recorded in  methanol. The 
presence of the glucose moiety induces chirality in the region of -* of the aromatic ring.27 
GluClHQ and GluMeHQ have similar CD spectra that show a slight negative band at 310 nm and a 
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more intense negative band at 200 nm. The CD spectrum of GluCl2HQ is significantly different and 
displays a positive band at 300 nm and two intense negative bands at 240 and 206 nm, respectively. 
The  values of GluCl2HQ spectrum are higher than the other two compounds, suggesting a 
different orientation of the aromatic ring respect to the sugar moiety in this case. This could be due 
to the presence of 7- substituent (a chlorine atom) given that a similar trend is observed for GluCQ. 
The CD spectra are perfectly consistent with NMR data.  
 
Figure 3. CD spectra of GluMeHQ (  ), GluClHQ (...), GluCl2HQ(---) in methanol. 
 
Copper complexes. Copper(II) complexes of  some hydroxyquinoline derivatives  have been 
investigated by different techniques.
28
 We investigated the coordination properties of MeHQ, ClHQ 
and Cl2HQ by ESI-MS. A picture of the metal–ligand complexes formed in solution can be 
obtained by the mass spectrometric data. The ESI-MS spectra in the positive mode of the 
hydroxyquinoline derivative solutions containing CuSO4 were recorded. The experiments were 
carried out at different pH, from 4.0 to 10.0. The formation of complex species was observed for pH 
> 5.  In Table 2 the pseudo-molecular ions of the observed species complexes are reported. The 
assignments of the peaks in ESI-MS spectra were done by comparing the experimental isotopic 
patterns with the corresponding simulated profiles. As expected, the three compounds can form 
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different complex species with copper (II). These data are in agreement with data previously 
reported in the literature for CQ and other similar compounds
28
.   
 
 
Table 2.  ESI-MS characterization of all the 
63
Cu
2+
 complexes  [Cu
2+
] = [L] = 3.0x10
-5 
M. 
L is a hydroxyquinolinate derivative. 
 
Ligand Assignment Calculated (m/z) Found (m/z) 
    
MeHQ [LH+H]
+
 160.1 160.1 
 [CuL +H2O]
+
 239.0 238.9 
 [CuL2 + H]
+
 380.1 379.9 
 [CuL2 +Na]
+
 402.0 401.9 
 [CuL2+K]
+
 418.0 418.0 
 [Cu2L3]
+
 600.0 599.8 
ClHQ [LH+H]
+ 180.0 180.1 
 [CuL+H2O]
+
 292.9 292.8 
 [CuL2+H]
+
 419.9 419.9 
 [CuL2+Na]
+ 
[Cu2L3]
+
 
441.9 
659.9 
441.9 
659.9 
Cl2HQ [LH+H]
+
 214.0 214.0 
 [CuL+H2O]
+ 
[CuL2+H]
+
 
274.9 
487.9 
274.9 
487.8 
 [CuL2+Na]
+ 
[Cu2L3]
+
 
509.9 
762.8 
487.8 
762.8 
 
Chemical and enzymatic stability. Chemical stabilities of the investigated compounds (Figure 1) 
were monitored by several techniques such as mass spectrometry, UV-vis spectroscopy and 
chromatography. 
 All glucoconjugates are very stable in the range of pH values (pH 4-11) and temperatures 
(25-37° C) investigated. No decomposition was detected after 24 hours under these conditions. In 
14 
 
particular, incubation of prodrugs at 37 °C in PBS (phosphate-buffered saline, pH 7.4) revealed that 
the prodrugs were stable for at least 1 week.  
 In order to evaluate the ability of prodrugs to release the active moiety in the presence of the 
specific enzyme, hydrolysis assays were carried out with β-glucosidase and monitored by several 
techniques, especially UV-vis spectroscopy. Almond β-glucosidase, commercially available, was 
used as the model enzyme. The UV-vis spectra were recorded at different time points to follow the 
hydrolysis at pH 7.4. When the glycoconjugates are hydrolized, the OHQ moiety is released and 
new bands due to the free oxine moiety appear. For comparison the same assay was repeated for the 
prodrugs in the absence of glucosidase and no modification of the bands was observed. The 
glucoconjugates showed different behaviour in the presence of β-glucosidase (Figure 4). The 
glycosidic bond of GluCl2HQ and GluClHQ was rapidly cleaved (within 40 min), showing that the 
glucoside trigger is readily accessible by the enzyme, despite the presence of bulky aromatic 
moieties. Oxine was released significantly faster from GluCl2HQ and GluClHQ than from GluCQ 
and GluOHQ. In contrast, GluMeHQ did not show any significative cleavage within 2 hours. 
However, GluMeHQ was partially cleaved in longer periods of times. Half-lives of prodrugs in the 
presence of β-glucosidase are reported in Table 3. 
Table 3. Half-lives of prodrugs in the presence of almond β-glucosidase (1.0x10-6M) at 37°C (pH 
7.0). 
 GluCl2HQ GluClHQ GluMeHQ GluCQ GluOHQ 
t1/2 (min) 9.5 26.5 >600 130.5 145 
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Figure 4. Hydrolysis of prodrugs in the presence of almond β-glucosidase (1.0x10-6M) at 37°C (pH 
7). GluClHQ (●), GluCl2HQ (▼), GluMeHQ (■), GluCQ (♦), GluOHQ (▲). 
 
Biological activities 
Antiproliferative activity. When analyzed for their antiproliferative activity against tumor A2780, 
A549 and MDA-MB-231 human cells, in the absence of Cu
2+
 ions, the investigated glycosides 
displayed discrete IC50s that ranged from 4.1 M to 55.3 M (mean±SD, 26.2±17.8 M), the 
exception being the glycoside GluMeHQ that displayed no activity (IC50>100 M) also in the 
presence of Cu
2+
 ion and, above all, compared to its not glycosylated counterpart (MeHQ, Table 4).  
 In the presence of 20 M Cu2+ we observed a deep reduction of IC50s for both the active 
compounds GluClHQ (mean reduction, 90±7%) and GluCl2HQ (mean reduction, 63±30%)(Table 
4), with compound GluClHQ that displayed a higher mean antiproliferative activity compared to 
GluCl2HQ (2.04±2.23 M vs 12.4±11.2 M). A similar increase of activity in the presence of the 
Cu
2+
 ion and a similar ratio between the mean antiproliferative activity were also observed for the 
parent compounds ClHQ and Cl2HQ (Table 4). 
As regard to the target cell lines, the breast cancer cell line MDA-MB-231 was the less sensitive 
target for both glycosylated and not glycosylated compounds in most culture conditions.  
16 
 
 
Effect of the inhibition of glycosidase activity. As shown in Figure 5, the presence in culture 
conditions of the -glycosidase inhibitor 2,5-dideoxy-2,5-imino-D-mannitol (DMDP) significantly 
increased the IC50 of both glycosylated compounds GluClHQ and GluCl2HQ. As negative control 
we also evaluated the antiproliferative activity of not glycosylated ClHQ and Cl2HQ compounds in 
the presence of DMDP. As expected in this case, no variation of the antiproliferative activity was 
observed demonstrating that glycosylated prodrugs may be activated only in the presence of an 
efficient -glycosidase activity that releases the active 8-hydroxyquinoline moiety.  
 
Table 4. Summary of IC50s (µM) of glycosides and their parent compounds on A2780, A549 and 
MDA-MB-231 cells  
 
a
 The numbers express the mean±SD of 4-8 data. 
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Figure 5. Histograms represent mean IC50s of glucosylated and not glucosylated hydroxyquinolines 
in the presence or absence of the -glucosidase inhibitor DMDP at 100 M concentration.  
 
Identification of apoptotic cells by DAPI and annexin V/PI stainings. Due to their 
pharmacologically significant antiproliferative activity both GluClHQ and GluCl2HQ and their not 
glycosylated parent compounds ClHQ and Cl2HQ were analyzed by DAPI staining for the 
triggering of apoptosis. In general, the compounds showed a pharmacologically relevant apoptotic 
activity that was higher when the Cu
2+ 
ions were present in culture. Compound Cl2HQ represented 
an exception to this general rule in fact, at both equitoxic concentrations, we did not observe 
significant differences in terms of apoptotic cells in the presence or absence of Cu
2+
 ions (Table 5). 
In order to confirm the previous data the GluClHQ and GluCl2HQ compounds were also analyzed 
for their ability to trigger apoptosis by the annexin V/PI staining. Once used at their IC50s these 
18 
 
compounds confirmed the previous results obtained by the microscopy observation of nuclear 
morphology after DAPI staining. In particular, these results showed that a higher early and/or late 
apoptotic activity was developed in the presence of Cu
2+
 ions (Figure 6). 
 
Table 5. Triggering of apoptosis by glucoconjugate compounds, as evaluated by nuclear 
morphological analysis after DAPI staining. 
 
a
 Each cell line was treated with the specific equitoxic concentrations IC50, as calculated by the 
MTT assay. 
b
 The means±SD (4-9 data) express the percentage of apoptotic cells. 
 
 
 
Figure 6.  Scatter plots of A2780 and A549 cells labeled with Annexin-V/PI after three days culture 
in the presence of GluClHQ and GluCl2HQ in the presence or absence of Cu
2+
 ions.
19 
 
Docking studies. The crystallographic structure of human cytosolic β-glucosidase29 (hCBG, PDB 
code 2JFE, Figure 7A) shows that the active site of the enzyme is located on the bottom of a deep 
pocket (Figure 7B). It can be divided into two parts; the recognition site for the glucose moiety 
located at the bottom of the active site and the binding site for the aglycone at the entrance of the 
pocket. The active site is shaped as an oval or slit-like pocket with a cluster of hydrophobic amino 
acid sidechains (in yellow in Figure 7B) lining the walls of the aglycone binding slot, whereas 
hydrophobic, polar and charged residues are present in the glycone binding moiety. 
2JFE provides useful 3D structural information for performing molecular docking studies. 
Investigated compounds were therefore docked to the binding cavity of 2JFE to evaluate their 
binding mode and affinity (kcal/mol).  
To do that among the plethora of docking softwares, AutoDock Vina
30 
was selected as main 
computational tool since it was recently used to model hydroxyquinolines in docking studies.
31
 The 
performances of AutoDock Vina were evaluated by reproducing the crystal structure of the complex 
of the maize -glucosidase (ZMGlu1) with the non-hydrolysable inhibitor p-nitrophenylbeta-D-
thioglucoside (PDB code: 1E1F). In this validation step we paid particular attention to check the 
position of the glycone moiety at the bottom of the active site close to the two catalytic residues 
(Glu165 and Glu373 shown in Figure 7A for hCBG). The orientation of the glycone moiety of the 
substrate was in fact used as a filter to evaluatehCBG docking results. In particular, we retained the 
best poses of any ligand (= the most stable) provided that their glycone moiety was located at the 
bottom of the active site. This was verified for the three best poses of all compounds. 
Results (Figure 7C-D) indicated that GluMeHQ has the best affinity for the binding site (-8.4 
kcal/mol for the best pose), whereas GluCl2HQ shows the lowest affinity (-7.04 kcal/mol for the 
best pose). The three remaining compounds show intermediate values. FLAP
32
 analysis confirmed 
this trend (data not shown). 
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Figure 7. A) The crystallographic structure of human cytosolic β-glucosidase (hCBG, PDB code 
2JFE); B) the active site of hCGB; the two catalytic residues (Glu165 and Glu373) are evidenced; 
C) The best poses of the five docked structures as obtained with AutoDock Vina abd; D) The best 
poses of the five docked structures in the active site (hydrophobic residues in yellow; hydrophilic 
residues in light blue). 
 
A B
DC
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Discussion 
 The main purpose of the study was the design of new compounds able to selectively target 
tumor cells exploiting  some of their specific biochemical features.  
 Firstly, as known and described before, tumor cells have the unique characteristic of 
containing elevated copper concentrations.
33, 34
  
 Secondly, tumor cells express an altered carbohydrate metabolism that is characterized by an 
elevated glycolysis that in turn justifies the glucose avidity described in the 50s by Otto Warburg 
and generated the idea of the so-called “Warburg effect”.35 This concept implies that tumor cells, 
due to their glucose avidity, possess an increased glucose transport caused by an over-expression of 
the glucose transporters.
36,37
  
 Finally, Arafa
38
 demonstrated that in the cancer cells used for his study the different β-
glucosidase activity profiles well correlated with the cytotoxicity rank order of the glucosides object 
of his research. This demonstration underlines the important role that these enzyme activities could 
have for the bioactivation of glycosilated prodrugs. This concept was not entirely new since 
previously other authors had identified this mechanism as essential for the activation of their 
glycosilated compounds.
39,40,41
 Taken together, all these works clearly demonstrate that the 
expression of the β-glucosidase or β-galactosidase activities is responsible for the bioactivation of 
the novel glycosilated prodrugs with the formation of the active aglycone moieties. Of course the 
level of expression of these enzymes into cancer cells remains an essential point distinguishing the 
pharmacological from the toxic effect of these compounds. On the whole a good balance between 
the β-glucosidase activity and the transmembrane glucose transporters may ensure the right and 
effective activation of glycosilated prodrugs
42
. In practice, high cellular β-glycosidase levels might 
be effective only when transport proteins are expressed as well. 
 An important future goal for the anticancer research is the oral administration of antitumor 
drugs that is expected to be accompanied by much greater patient tolerability and reduced 
associated cost. To reach this aim the application in the early stages of the drug discovery process 
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of knowledge of the compound’s absorption, distribution, metabolism and excretion (ADME) 
profile is mandatory. In fact the optimization of the ADME profile is expected to significantly 
improve the candidates ‘druggability’43 and in fact few of the anticancer drugs currently in the 
clinic have optimized ADME features.
44
 Also solubility issues should be taken into consideration. 
Here we designed compounds that are predicted to show drug-like physicochemical properties since 
they are all within the range set by Lipinski’s Ro5. Moreover, prodrugs are predicted to be 
significantly more soluble than parent compounds. Finally, ADME in silico data predict a good 
pharmacokinetic profile at least for distribution and metabolism events.  
 GluClHQ, GluCl2HQ and GluMeHQ were synthetized in good yields with a straightforward 
procedure. The synthesis was optimized in order to obtain the pure β-anomer in a one-pot reaction. 
The β-anomers were the compounds of interest in this study because the tumor cells generally have 
a high expression of β-glucosidase. The desired products have been fully characterized by NMR, 
UV-Vis, CD, and ESI-MS. The purity of compounds has been confirmed by different techniques. 
The compounds were obtained pure without the use of elaborate processes of purification. This 
aspect is very important, considering one of the main reasons of CQ withdrawal from the market 
was the presence of di-iodo impurities. Furthermore, O-glycosylation of compounds masks the 
metal binding site, thereby preventing systemic chelation. This is the reason why the glucosides are 
not able to complex metal ions. The pyridine ring can complex copper(II) only with a log K1 about 
2.6
45
, thus the glucose moiety has to be cleaved before efficient metal chelation of the quinolone 
ring. 
 ClHQ, Cl2HQ and MeHQ are able to complex metal copper(II) with good stability 
constants,
45
  forming CuL and CuL2 as main species. The amount of each complex species depends 
on the concentration of copper(II) and the ligands.  
 We have already described
22
 that the presence of Cu
2+
 ions makes glycosylated compounds 
more active in terms of antiproliferative activity than in culture conditions characterized by lower 
Cu
2+
 concentration. This difference is confirmed by present data where the presence of a high Cu
2+
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concentration improved the activity of investigated derivatives by about ten times. The presence of 
a discrete activity in the absence of added Cu
2+
 ions may be ascribed to the possible high Cu
2+ 
content of tumor cells utilized for our tests in vitro. It is also worth noting that ClHQ is the most 
active hydroxyquinoline of the series here studied, with IC50 ranging between 5.12±0.94 M and 
18.7±5.9 M.  
 An important result of the study is finding that glycosilated compounds have an 
antiproliferative activity nearly similar to that of their parent compound except for the methyl 
derivative that showed a very low activity in all three cell lines used for our in vitro tests.  
These data are consistent with the glucosidase cleavage assay in vitro and docking studies. 
Experimental cleavage studies suggest that the glucoconjugates are not hydrolyzed in the same way 
by glucosidase. In fact GluMeHQ, which results inactive in the antiproliferative assay, is the 
compound cleaved in longer times in comparison to the other glycosydes. These experimental 
results are supported by docking studies that show that prodrugs with high t1/2 are tighter bound to 
the active site than those with low t1/2. This trend is verified by using two docking algorithms 
showing very different theoretical approaches and could suggest that compounds that are too tightly 
bound to the enzyme are slowly hydrolised. We are also aware that this relationship between 
experimental and computational data should be considered with caution for at least two reasons. 
Firstly, it is known that the active site of -glucosidases is well-conserved, but here experimental 
and computational data were obtained using two different enzymes, almond glucosidase and hCBG, 
respectively. Secondly, it must be kept in mind that docking calculations can simulate only the 
recognition phase between enzyme and substrates and give no information on the whole 
enzymatic phenomenon.  
 As for the apoptosis, the opinion, initially quite controversial, that this death mechanism 
plays an essential role in the response to the chemotherapeutics,
46,47
 has now been considered  a 
landmark for anticancer drug research and for new chemotherapy-based procedures. It is well 
known that apoptosis represents, together with necrosis, an important pathway of cell death after 
24 
 
chemotherapy. Thus the evaluation of the triggering of apoptosis by the new compounds with 
anticancer activity becomes necessary both in in vitro and in vivo studies.
48,49
 In the case of our 
glucoconjugates it is worth noting that their antiproliferative activity was always developed together 
with  a significant triggering of this important and essential death event for chemotherapeutic agents 
and that this was in general higher when Cu
2+
 ions were added to the culture medium at equitoxic 
conditions of antiproliferative activity. The only exception to this rule is the use of Cl2HQ where the 
presence of Cu
2+
 ions does not imply an increased apoptosis. 
 In order to verify that the glucosidase enzymatic activation of glucoconjugates is crucial for 
their antiproliferative activity we also performed antiproliferative experiments in the presence of 
Cu
2+
 ions and the known β-glucosidase inhibitor DMDP. Interestingly, the IC50s of the most active 
glycosilated hydroxylquinolines GluClHQ and GluCl2HQ, after treatment with DMDP, 
significantly increased by several times, while DMDP did not affect the activities of the parent 
compounds. These data unequivocally confirm the importance of the presence of -glucosidase 
activity to allow the release of the active quinoline moiety in order to develop the antiproliferative 
activity after the binding of the Cu
2+
 ions. 
 The differences in sensitivity between the cell lines, in particular the lower sensitivity of the 
breast cancer cell line MDA-MB-231, could be interpreted on the basis of the absence of a 
sufficient number of glucose-transporters since the level of -glucosidase (data not shown) were 
similar to those observed in the other two cell lines A2780 and A549. Opportune dosages of the 
concentration of membrane glucose-transporters could better explain our results.  
 A final point to be highlighted concerns the mechanism of action of OHQs as anticancer 
agents. In the last few years the ubiquitin-proteasome system (UPS) has emerged as a possible 
target for new anticancer compounds due to its involvement in the regulation and control of 
important protein in turn involved in vital cell mechanisms, such as proliferation, signal 
transduction, gene trascription, DNA repair and apoptosis.
50
 The UPS acts in the turnover of 
proteins thanks to the involvement of tens of genes
51,52
 some of which code enzymes working in 
25 
 
processes, such as the protein ubiquitination and deubiquitination with very specific mechanisms of 
targeting.
53
 At present the bulk work on the UPS has led to the synthesis and clinical use of 
Bortezomib, an anticancer drug specific for the chymotripsin-like activity of proteasome whose 
inhibition seems to be directly involved in the induction of apoptosis in tumors,
54
 which is mainly 
used in clinics for the treatment of myeloma.
55
 Other hydroxyquinolines have as main mechanism 
of action the ability to interact with the UPS, in particular with the chymotripsin-like activity of 
proteasome, causing the arrest of the cell cycle and the triggering of apoptosis. The glycosilated 
compounds object of this study, by analogy, could have the same mechanism of action once 
deprived of the glucose moiety thanks to the action of -glucosidase. 
 
Conclusion  
 We designed and synthesized new glucoconjugates of OHQ derivatives built exploiting 
three frequent features of cancer cells, such as the high expression and content of -glycosidase 
activity and Cu
2+
 concentration, and the high membrane concentration of glucose transporters 
linked to the “natural” glucose avidity of tumors. We show that these features can be synergistically 
combined to obtain new compounds highly specific for neoplastic cells. Physicochemical and 
ADME considerations were also included in the design phase of the project. The exploitation of 
these characteristics, all contained in a single molecule should, not only allow for a better selection 
of target tumor cells, but also minimize the chemotherapeutic side effects.  
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Experimental Section 
Materials. Commercially available reagents were used directly, unless otherwise noted. 5-chloro-8-
quinolinol (ClHQ), 5,7-dichloro-8-quinolinol (Cl2HQ), 2-methyl-8-quinolinol (MeHQ) were 
purchased by Sigma-Aldrich. TLC was carried out on silica gel plates (Merck 60-F254). β-
Glucosidase from almonds was obtained from Sigma-Aldrich. 
 
NMR spectroscopy. 
1
H and 
13
C NMR spectra were recorded at 25°C with a Varian UNITY PLUS-
500 spectrometer at 499.889 and at 125.7 MHz respectively. The NMR spectra were obtained by 
using standard pulse programs from Varian library. The 2D experiments (COSY, TOCSY, 
gHSQCAD. gHMBC) were acquired using 1K data points, 256 increments and a relaxation delay of 
1.2 s.  
 
Mass spectrometry, UV-vis and circular dichroism spectroscopy. The ESI-MS measurements 
were performed on a Finnigan LCQ-Duo ion trap electrospray mass spectrometer. The UV spectra 
were recorded using an Agilent 8452A diode array spectrophotometer. CD measurements were 
performed under a constant flow of nitrogen on a JASCO model J-810 spectropolarimeter. The 
spectra represent the average of 10 scans and were recorded at 25°C, on freshly prepared methanol 
solutions. 
 
General procedure for the synthesis of the glucoconjugates. 8-Quinolinol derivative (0.75 
mmol) and K2CO3 (7.5 mmol) were added to water (50 mL) and methanol (40 mL). 
Dichloromethane (100 mL) was added to this aqueous solution, followed by acetobromoglucose 
(1.88 mmol) and tetrabutylammonium bromide (0.75 mmol). The resulting mixture was vigorously 
stirred for 68 h. As for, ClHQ and Cl2HQ, a solid precipitated, and the deacetylated products were 
collected by filtration, washed with cool methanol and dried. As for, MeHQ, the two-phase system 
was separated, and the aqueous phase was washed repeatedly with dichloromethane. The aqueous 
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phase was partially evaporated under vacuum to remove residual organic solvents and then a white 
solid precipitated. The product was collected by filtration washed with cool methanol and dried. 
The purity was assayed by HPLC (Varian Prepstar instrument equipped with a Prostar 330 
photodiode array detector. Column: Econosphere ODS (Alltech) column (5 μm, 2.0×250 nm), 
eluent: linear gradient water CH3CN). 
 
5-chloro-8-quinolinyl-β-D-glucopyranoside (GluClHQ). Yield: 68%. TLC: Rf=0.51 
(PrOH/AcOEt/H2O/NH3 4:4:1:1). HPLC Purity 98%. 
ESI-MS: m/z=341.85 [GluClHQ+H]
+
, 363.92 [GluClHQ+Na]
+
, 704.61 [2GluClHQ+Na]
+
  
1
H NMR (500 MHz, CD3OD) δ (ppm): 8.97 (dd, J2,3 = 4.3, J2,4 = 1.6 Hz, 1H, H-2), 8.71 (dd, J4,3 = 
8.6, J4,2 = 1.6 Hz, 1H, H-4), 7.75 (dd, J3,4 = 8.6, J3,2 = 4.3 Hz, 1H, H-3), 7.67 (d, J6,7 = 8.5 Hz, 1H, 
H-6), 7.51 (d, J7,6 = 8.5 Hz, 1H, H-7), 5.09 (d, J1,2= 7.8 Hz, 1H, H-1 of Glu), 3.97 (dd, J6a,6b = 12.1, 
J6a,5=2.2 Hz, 1H, H-6a of Glu), 3.81 – 3.64 (m, 2H, H-2 and H-6b of Glu), 3.60-3-54 (m, 2H, H-3, 
H-5), 3.45 (dd, J = 9.6, 9.0 Hz, 1H, H-4). 
  
13
C NMR (125 MHz, CD3OD) δ (ppm): 153.2 (C-8), 151.1 (C-2), 140.9 (C-9), 135.1 (C-4), 128.4 
(C-6, C-5), 125.0 (C-10), 124.1 (C-3), 114.5 (C-7), 103.3 (C-1 of Glu), 78.6 (C-5 of Glu), 77.4 (C-
3), 74.7 (C-2 of Glu), 71.6 (C-4 of Glu), 63.0 (C-6 of Glu). 
UV-Vis: (CH3OH) λ/nm (ε): 243 (25600), 317 (3360).   
CD (CH3OH) λ/nm (Δε): 197.8 (-4.24), 311.4 (-0.70). 
Elemental analysis for C15H16NClO6·H2O: calc. C 50.06; H 5.05; N 3.89; found C, 50.00; H, 4.99; 
N, 3.94. 
 
5,7-dichloro- 8-quinolinyl-β-D-glucopyranoside (GluCl2HQ). Yield: 61%. TLC: Rf=0.52 
(PrOH/AcOEt/H2O/NH3 4:4:1:1). HPLC Purity 98%. ESI-MS: m/z=375.85 [GluCl2HQ+H]
+
, 
397.92 [GluCl2HQ+Na]
+
, 772.51 [2GluCl2HQ+Na]
 +
. 
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1
H NMR (500 MHz, CD3OD) δ (ppm): 8.98 (dd, J2,3 = 4.3Hz, J2,4 = 1.5 Hz, 1H, H-2), 8.68 (dd, J4,3  
= 8.6, J4,2 = 1.6 Hz, 1H, H-4), 7.82 (s, 1H, H-6), 7.72 (dd, J3,4 = 8.6, J3,2 = 4.3 Hz, 1H, H-3), 5.34 (d, 
J1,2 = 7.8 Hz, 1H, H-1 of Glu), 3.77 (dd, J6a,6b =11.9, J6a,5= 2.4 Hz, 1H, H-6a), 3.72 (dd, J2,3  = 8.8, 
J2,1 = 7.8 Hz, 1H, H-2), 3.66 (dd, J6b,6a = 11.9, J6b,5= 5.3 Hz, 1H, H-6b) 3.50 – 3.42 (m, 2H, H-4, H-
3), 3.23 (ddd, J5,4 = 9.4, J5,6b = 5.3,  J5,6a = 2.3 Hz, 1H, H-5). 
  
13
C NMR (125 MHz, CD3OD) δ (ppm): 152.3 (C-2), 143.4 (C-8), 144.1 (C-9), 135.6 (C-4), 130.0 
(C-6), 129.2 (C-7), 128.5 (C-5), 127.8 (C-10), 124.2 (C-3), 107.3 (C-1 of Glu), 78.6 (C-5 of Glu), 
78.4 (C-3), 72.2 (C-2 of Glu), 71.3 (C-4 of Glu), 62.7 (C-6 of Glu). 
UV-Vis (CH3OH) λ/nm (ε) : 207 (20900), 242 (24800), 302 (3020). 
CD (CH3OH) λ/nm (Δε): 206.6 (-5.10), 240.2 (-10.77), 318.0 (0.73). 
Elemental analysis for C15H15NCl2O6·H2O: calc. C 45.68; H 4.35; N 3.55; found C, 45.59; H, 4.30; 
N, 3.58. 
 
2-methyl-8-quinolinyl-β-D-glucopyranoside (GluMeHQ). Yield: 57%. TLC: Rf=0.44 
(PrOH/AcOEt/H2O/NH3 4:4:1:1). HPLC Purity 98%. ESI-MS: m/z= 321.94 [GluMeHQ+H]
+
, 
344.00 [GluMeHQ+Na]
+
 359.87 [GluMeHQ+K]+ 664.61 [2GluMeHQ+Na]+, 680.80 
[2GluMeHQ+K]
+
. 
1
H NMR (500 MHz, CD3OD) δ (ppm): 8.24 (d, J 4,3 = 8.4 Hz, 1H, H-4), 7.56 (dd,  J5,6 = 6.8, J5,7 = 
2.7 Hz, 1H, H-5), 7.48 (m, 3H, other aromatic H), 5.05 (d, 1H,  J1,2= 7.8. Hz, H-1 of Glu), 3.96 (dd,  
1H, J6a,6b = 12.1, J6a,5 = 2.2 Hz, H-6a of Glu), 3.75  (dd, 1H, J6a,6b = 12.1, J6b,5 = 15.0 Hz,  H-6b of 
Glu), 3.73 (t, 1H, H-2 of Glu), 3.56 (m, 2H, H-5 and H-3 of Glu), 3.46 (t, 1H, J4,3 =J4,5 = 18 Hz, H-
4 of Glu), 2.77 (s, 3H, CH3).  
13
C NMR (125 MHz, CD3OD) δ (ppm): 154.5 (C-2),  148.0 (C-8), 133.2 (C-9),  134.7 (C-4), 123.6 
(C-6, C-10), 120.3 (C-3), 118.9 (C-5), 111.5 (C-7), 105.3 (C-1 of Glu), 77.0 (C-3 and C-5 of Glu), 
74.7 (C-2 of Glu), 69.8 (C-4 of Glu), 61.2 (C-6 of Glu), 20.8 (CH3). 
UV-Vis (CH3OH) λ/nm (ε): 204 (31700), 240 (32200), 297 (3110). 
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CD (CH3OH) λ/nm (Δε): 196.8 (-2.68), 312.6 (-0.34). 
Elemental analysis for C15H15NO6·H2O: calc. C 56.62; H 6.24; N 4.13; found C, 56.65; H, 6.21; N, 
4.09.  
 
Copper(II) complex studies. The copper(II) complexes were prepared by adding a solution of 
CuSO4 to a ligand solution in 1:1 ratio. ClHQ and Cl2HQ are poorly soluble in water and their metal 
complexes were examined in a methanol/water mixture (80/20 w/w).  
 All the ESI-MS measurements were carried out by using a Finnigan LCQ DECA XP PLUS 
ion trap spectrometer operating in the positive ion mode and equipped with an orthogonal ESI 
source (Thermo Electron Corporation, USA). Sample solutions were injected into the ion source 
without the addition of any other solvent at a flow rate of 5 μL/ min. For electrospray ionization the 
drying gas (N2) was heated at 270 °C. The capillary exit and skimmer voltage were varying in order 
to optimize the signal responses. Scanning was performed from m/z=100 to 2000 and no 
fragmentation processes were observed under our experimental conditions. Xcalibur software was 
used for the elaboration of mass spectra. Each species is indicated with the m/z value of the first 
peak of its isotopic cluster. 
 
In vitro stabilities of glucoconjugates. The three final compounds were incubated at 37° C in PBS 
to monitor their stabilities by TLC, ESI-MS and UV-Vis spectroscopy. Furthermore, the compound 
stability was monitored at pH 4 and 11. 
 
Enzymatic cleavage assay. Glycoconjugates were incubated at 37 °C for 2 h. TLC and ESI-MS 
monitoring of the glucosidase reactions were used to determine whether the clioquinol glycosides 
showed any sign of being cleaved by the enzyme. Enzymatic cleavage was also monitored by UV-
vis spectroscopy. Unless stated otherwise, β-glucosidase (1.0×10−6 M) was incubated in the assay 
solution in the presence of the glycoconjugates (5.0×10
−5
 M) at 37 °C. Samples (2 mL) were 
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removed at selected time points over 4h and were immediately added with a solution of NaOH until 
the pH value of the solution reached 11.0 in order to stop enzymatic activity. Furthermore at this pH 
the released drug show a shift of the bands because of the deprotonation of phenolic group and so it 
is possible to quantify the released drug through UV-vis spectroscopy. Calibration curves of the free 
ligands for absorbance against their concentrations were obtained at pH 11.0.  The UV-vis spectra 
were recorded in 1.0 cm path length matched quartz cuvettes with an Agilent 8452A diode array 
spectrophotometer at 37 °C.  All assays were performed in triplicate. 
 
Dilution of glycosides and parent compounds for biological determinations. All glycosides and 
parent compounds were firstly dissolved in 100% dimethylsulfoxide (DMSO) at the concentration 
of 100 mM and then further diluted in fetal calf serum (FCS, final concentration DMSO 0.2-0.4%).  
 
Determination of antiproliferative activity by the MTT assay. Human cell lines A549 (lung, 
carcinoma), A2780 (ovary, adenocarcinoma), and MDA-MB-231 (breast, carcinoma) were plated at 
10
5
/ml, 0.89 x 10
5
/mL and 2 X 10
5
/mL, respectively, in 180 l complete medium into flat-bottomed 
96-well microtiter plates. After 6-8 hours cells were treated with 20 l containing five 1:10 fold 
concentrations of our compounds diluted in FCS containing 2% or 4% DMSO in the presence or 
absence of CuCl2
 
salt (20 M). After 72 hours plates were processed and IC50s values calculated as 
described elsewhere.
56
 Each experiment was repeated 4-8 times. 
 
Inhibition of glucosidase activity. The evaluation of antiproliferative activity was performed on 
A2780 and A549 cells in the presence of Cu
2+
 ions and 100 M of the -glycosidase inhibitor 2,5-
dideoxy-2,5-imino-D-mannitol (DMDP). The same experiments were carried out without DMDP as 
a control. 
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Microscopy visualization of apoptotic cells after 4'-6-diamidino-2-phenylindole (DAPI) 
staining. A2780, A549 and MDA-MB-231 were plated in 24-well plates at their optimal 
densities/well (see above) in 1 ml complete medium for 6-8 h. ClHQ, Cl2HQ and their glycosylated 
counterparts were then added to obtain their specific final IC50, as determined by the MTT assay. 
After 72 hours floating and adherent cells were harvested, washed twice with cold PBS, fixed with 
60 L of 70% ethanol in PBS and maintained at 4 °C until analysis. For microscopy examination 5 
L of 10 g/ml DAPI in water were added to the samples, and the percentage of apoptotic 
segmented nuclei/cells evaluated. 
 
Evaluation of apoptosis by annexin-V/PI staining. The triggering of apoptosis was also evaluated 
for the glycosylated compounds Glu-ClHQ and Glu-Cl2HQ in A2780, and A549 cells. Cells were 
treated with the specific IC50 of each compound in the presence or absence of Cu
++ 
salt (20 M). 
Three days after floating and adherent cells were harvested, washed with cold PBS and early and 
late apoptotic cells determined by double staining with FITC-annexin-V/PI (rh Annexin-V/FITC 
Kit, Bender MedSystem GmbH, Vienna, Austria). The subsequent analysis was performed by flow 
cytometry as described elsewhere.
57
  
 
Physicochemical and ADME profile. Solubility (expressed as ALOGpS, the higher, the more 
soluble the compound) was calculated with VCCLAB, Virtual Computational Chemistry 
Laboratory, http://www.vcclab.org, 2005.
58
  The conformational hypersurface of compounds was 
explored with the standard conformational search module implemented in MOE2009.10. Virtual 
log P calculations were performed with VEGA ZZ 3.0.0 (http://www.vegazz.net). 
The 3D structures (see below) were submitted to VolSurf+ (version 1.0.4, Molecular Discovery 
Ltd. Pinner, Middlesex, UK, 2009, http://www.moldiscovery.com)
59
 using default settings and four 
probes (OH2, DRY N1 and O probes that mimic respectively water, hydrophobic, hydrogen bond 
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acceptor and hydrogen bond donor interaction of the compounds with the environment). The 
molecules were projected on the pre-calculated models implemented in VolSurf+ to calculate Ro5 
and ADME parameters. 
 
Molecular docking. The crystal structure of human cytosolic β-glucosidase was obtained from the 
RCSB Protein Data Bank, code 2JFE. The 3D structure was visualized and modified with Pymol 
v1.1.r1 as follows. Water and NAG molecules were removed, hydrogen atoms were added and the 
resulting structure was saved in the pdb format. Ligands were built using CORINA
60
 and saved in 
the mol2 format. AutoDock Vina
30
  and FLAP UI version 0.43.0
32
 were used to perform docking 
studies. The active site in AutoDock was defined by the coordinates  of C of the catalytic residue 
Glu165 (33 (X), 51 (Y) and 38 (Z)).
29
 To ensure a correct docking process, the search space was 
defined to encompass all flexible residues as a box with dimensions of 30.0 × 30.0 × 30.0 Å. Ligand 
Explorer v.3.9 was used to visualize the interactions of bound ligands in the protein. 
 
Statistical analysis. The Mann-Whitney test for non-parametric data was used for the statistical 
analysis of data. 
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Supporting Information. 
1
H NMR spectra (COSY, TOCSY, HMQC, HSQC), 
13
C NMR spectra 
and MS-ESI spectra for all prodrugs. UV-Vis spectra used for kinetic experiments. 
 
Abbreviations used. CQ, clioquinol; OHQ, 8-hydroxyquinoline; AD, Alzheimer Disease; GLUT, 
glucose transporter; ADME, absorption, distribution, metabolism and excretion; CD, circular 
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dichroism; TLC, thin layer chromatography; DMDP, 2,5-dideoxy-2,5-imino-D-mannitol; DMSO, 
dimethylsulfoxide; PBS, phosphate buffered saline, FCS, fetal calf serum; DAPI, 4'-6-diamidino-2-
phenylindole; UPS, ubiquitin-proteasome system; MTT,  3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide; hCBG, human cytosolic β-glucosidase.  
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